Zach Butzin-Dozier, Ph.D.

Publications

Zach Butzin-Dozier, Ph.D.; Sky Qiu; Alan Hubbard, Ph.D.; Seraphina Shi; Mark van der Laan, Ph.D.
Journal Article, 2024
Zach Butzin-Dozier, Ph.D.; Yunwen Ji; Haodong Li; Jeremy Coyle; Seraphina Shi; Rachael Phillips, Ph.D.; Andrew Mertens; Romain Pirracchio, M.D., MPH, Ph.D, FCCM; Mark van der Laan, Ph.D.; Rena C Patel; John M Colford; Alan Hubbard, Ph.D.
Journal Article, 2024
Zach Butzin-Dozier, Ph.D.; Andrew Mertens; Sophia T. Tan; Douglas A. Granger; Helen O. Pitchik; Dora Il'yasova; Fahmida Tofail; Md. Ziaur Rahman; Ivan Spasojevic; Idan Shalev; Shahjahan Ali; Mohammed Rabiul Karim; Sunny Shahriar; Syeda Luthfa Famida; Gabrielle Shuman; Abul K. Shoab; Salma Akther; Md. Saheen Hossen; Palash Mutsuddi; Mahbubur Rahman; Leanne Unicomb; Kishor K. Das; Liying Yan; Ann Meyer; Christine P. Stewart; Alan Hubbard, Ph.D.; Ruchira Tabassum Naved; Kausar Parvin; Md. Mahfuz Al Mamun; Stephen P. Luby; John M. Colford Jr.; Lia C.H. Fernald; Audrie Lin
Journal Article, 2024
Department: 
Epidemiology
Bio/CV: 

Zach is a postdoctoral scholar in the Division of Biostatistics at the UC Berkeley School of Public Health working under Professors Alan Hubbard, Jack Colford, and Mark van der Laan. His work applies Targeted Machine Learning methodology to data from the National COVID Cohorts Collaborative (N3C) to evaluate protective interventions against Long COVID, including COVID-19 vaccination, selective serotonin reuptake inhibitors (SSRIs), metformin, and immune-modulating drugs. He led a research team that placed third in the NIH Long COVID Computational Challenge for building an ensemble machine learning model that predicted individual risk of Long COVID diagnosis. His previous work evaluated drivers of child growth and development in rural Bangladesh through the WASH Benefits study. He received his Ph.D. in Epidemiology and MPH in Epidemiology and Biostatistics from UC Berkeley.

Research interests: 
Causal inference, targeted machine learning, synthetic data, adaptive trial design, optimal treatment regimes, child development, stress neurobiology, and antimicrobial resistance